Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Rewired ERK-JNK signaling pathways in melanoma.

Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, Smalley KS, Mahale A, Eroshkin A, Aaronson S, Ronai Z.

Cancer Cell. 2007 May;11(5):447-60.

2.
3.

Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells.

Yu J, Guo QL, You QD, Zhao L, Gu HY, Yang Y, Zhang HW, Tan Z, Wang X.

Carcinogenesis. 2007 Mar;28(3):632-8. Epub 2006 Sep 28.

4.

Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.

Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, Chiosis G, Golub TR.

Cancer Cell. 2006 Oct;10(4):321-30. Epub 2006 Sep 28.

5.

Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid.

Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K, Hong YS, Lee JJ.

Biochem Pharmacol. 2006 Nov 15;72(10):1311-21. Epub 2006 Sep 18.

PMID:
16984800
6.

Mechanisms of crosstalk between TNF-induced NF-kappaB and JNK activation in hepatocytes.

Wullaert A, Heyninck K, Beyaert R.

Biochem Pharmacol. 2006 Oct 30;72(9):1090-101. Epub 2006 Aug 24. Review.

PMID:
16934229
7.

Malignant melanoma: genetics and therapeutics in the genomic era.

Chin L, Garraway LA, Fisher DE.

Genes Dev. 2006 Aug 15;20(16):2149-82. Review.

8.

MITF: master regulator of melanocyte development and melanoma oncogene.

Levy C, Khaled M, Fisher DE.

Trends Mol Med. 2006 Sep;12(9):406-14. Epub 2006 Aug 8. Review.

PMID:
16899407
9.

Recent advances in melanoma research.

Reed JA, Medrano EE.

Front Biosci. 2006 Sep 1;11:3003-13. Review.

PMID:
16720371
11.

Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma.

Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EA.

Oncogene. 2006 Jun 29;25(28):3956-62. Epub 2006 Feb 13.

PMID:
16474847
12.

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG.

J Invest Dermatol. 2006 Jan;126(1):154-60.

13.

V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.

Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D, Rosen N.

Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):57-62. Epub 2005 Dec 21.

14.

The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation.

Bedogni B, Welford SM, Cassarino DS, Nickoloff BJ, Giaccia AJ, Powell MB.

Cancer Cell. 2005 Dec;8(6):443-54.

15.

Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction.

Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, Rimm DL, Bar-Eli M.

Cancer Res. 2005 Dec 1;65(23):11185-92.

16.
17.

Distinct sets of genetic alterations in melanoma.

Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC.

N Engl J Med. 2005 Nov 17;353(20):2135-47.

18.

Increased radiation-induced apoptosis of Saos2 cells via inhibition of NFkappaB: a role for c-Jun N-terminal kinase.

Eliseev RA, Zuscik MJ, Schwarz EM, O'Keefe RJ, Drissi H, Rosier RN.

J Cell Biochem. 2005 Dec 15;96(6):1262-73.

PMID:
16167336
19.

RACK1 mediates activation of JNK by protein kinase C [corrected].

López-Bergami P, Habelhah H, Bhoumik A, Zhang W, Wang LH, Ronai Z.

Mol Cell. 2005 Aug 5;19(3):309-20. Erratum in: Mol Cell. 2005 Aug 19;19(4):578-9.

20.

Rb/E2F: a two-edged sword in the melanocytic system.

Halaban R.

Cancer Metastasis Rev. 2005 Jun;24(2):339-56. Review.

PMID:
15986142
Items per page

Supplemental Content

Write to the Help Desk